Xcout Intel
Adela, Inc.
Adela, Inc. is an epigenomics-focused biotechnology company headquartered in Foster City, California. The company is advancing breakthrough approaches for the early detection of multiple types of cancer through blood tests.
Subscribe to see Adela, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Adela, Inc. at a glance
Adela, Inc. is a diagnostics/tools company headquartered in United States, founded in 2020. Its most recent funding round raised $5M in April 2026. Xcout tracks 15 named people at Adela, Inc., including Priscilla Huang (Senior Vice President of Finance, Treasurer and Secretary).
Adela, Inc. leadership
- Priscilla HuangSenior Vice President of Finance, Treasurer and Secretary
- Alan WilliamsExecutive Officer
- Anne-Renee HartmanExecutive Officer
- Daniel Diniz De CarvalhoExecutive Officer
- David ScheerExecutive Officer
- Lindsay MateoExecutive Officer
9 more named people on record for Adela, Inc., with roles, board committees and tenure — see the full roster →
Adela, Inc. funding rounds
The 5 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $5M | — | |
| SEC Form D filing | $25.4M | — | |
| SEC Form D filing | $3.3M | — | |
| SEC Form D filing | $48.5M | — | |
| SEC Form D filing | $1.2M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Adela, Inc. competitors
A few of Adela, Inc.'s closest competitors — see the full list of competitors and alternatives →
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Precede Biosciences is a biotechnology company developing blood-based liquid-biopsy technologies for molecular profiling of cancer. Its tests are intended to support oncology research, precision treatment decisions, and pharmaceutical drug-development programs.
Epigenomics AG is a molecular diagnostics company headquartered in Berlin, Germany with a wholly owned subsidiary, Epigenomics Inc. based in Seattle, WA.
Predicta Biosciences is a precision oncology company that builds a molecular insights platform for blood cancer care. By utilizing a single blood sample, the company integrates multiomics and liquid biopsies to generate longitudinal genomic and immune insights for diagnostics.
Nucleix is a liquid biopsy company headquartered in Rehovot, Israel. It aims to revolutionize cancer treatment through earlier disease detection, focusing on interventions that can bring the greatest impact.
GRAIL, Inc. is an innovative commercial-stage healthcare and life sciences company headquartered in Menlo Park, California, focused on early cancer detection technologies. The company was acquired by Illumina in 2021.
Get Adela, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Adela, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Adela, Inc. in Xcout Intel
- 15 named people with titles, LinkedIn and board committees
- 6 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access